<DOC>
	<DOC>NCT00437255</DOC>
	<brief_summary>Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.</brief_summary>
	<brief_title>Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis</brief_title>
	<detailed_description>Same as above.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Moderate to severe psoriasis involving 320% of the body surface area Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® Spray or more than 100 grams per week of Taclonex® Ointment Subjects having psoriasis that involves the scalp, face, or groin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>